Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

Biotech Showcase™ returns to San Francisco during J.P. Morgan Healthcare Week, marking its 19 th year as a premier ...

BMO pointed to Gilead, Eli Lilly, Regeneron and Merck from the pharma world as names to watch for 2026. “With what felt like sector whiplash in 2025, we remain optimistic into 2026,” the team’s ...

Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s ...

The U.S. has been adept at inventing The Next Big Thing, but sometimes stumbles when it comes to exploiting it. From cars to electronics, solar panels, and semiconductors, this pattern has been ...

Investing in the biotech industry can be a long road to gains given the sector’s volatility. Even with a good understanding of the system, no one can predict which treatment, device or therapy will ...

Price action of IBB from the past is studied to suggest that the sectoral bottom might be in. Correction of 2014 is explored in detail to study how the bottoming process in biotech has worked in the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The funding follows $2.1 million in pre-seed funding the ...